Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4‐FHDH)

S. Abgrall,H. Selinger‐Leneman,E. Lanoy,A. Becker,S. Matheron,P. de Truchis,J. Pavie,A. Canestri,M. A. Khuong,D. Rey,F. Caby,P. Tattevin,R. Palich,S. Grabar,on behalf of ANRS CO4‐FHDH
DOI: https://doi.org/10.1111/hiv.13729
2024-11-06
HIV Medicine
Abstract:Background Assessing the potential increased risk of viral rebound (VR) in migrants requires adequate control for sex and acquisition risk groups. Methods People living with HIV1, enrolled in the ANRS CO4‐French Hospital Database on HIV, who achieved virological suppression with antiretroviral therapy (ART) initiated between 2006 and 2016 were included. We first compared the risk of VR, with loss to follow‐up and death considered as competing events, across origin among the HIV acquisition groups, then across acquisition groups among the different origins, and finally across modality of a variable combining sex, acquisition group, and origin. Models were adjusted for clinical and biological confounding factors. Results We included 21 571 French natives (FRA), 10 148 migrants from sub‐Saharan Africa (SSA), 1137 migrants from the non‐French West Indies (NFWI), and 4205 other migrants (OTHER). The 5‐year probability of VR was 19% (95% confidence interval [CI] 19–20) overall, 15% in FRA, 21% in OTHER, 26% in SSA, and 34% in NFWI (p
infectious diseases
What problem does this paper attempt to address?